Mark Coleman, Director at Axsome Therapeutics, Inc. (AXSM), bought 650 shares at $78.50 ($51K) on 2020-06-29, disclosed to the SEC on 2020-06-30.
Open-market purchase of $51k AXSM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| Filing → |
| AXSM | SELL | 2026-02-27 | $4.0M | — | Filing → |
| AXSM | BUY | 2025-09-09 | $263K | — | Filing → |
| AXSM | SELL | 2025-05-29 | $1.6M | — | Filing → |